Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.44M Buy
54,733
+27,150
+98% +$1.89M 0.03% 508
2025
Q4
$1.83M Sell
27,583
-20,255
-42% -$1.31M 0.01% 613
2025
Q3
$3.22M Buy
47,838
+44,789
+1,469% +$3.54M 0.03% 405
2025
Q2
$266K Sell
3,049
-34
-1% -$2.67K ﹤0.01% 1019
2025
Q1
$211K Sell
3,083
-237
-7% -$19.3K ﹤0.01% 1038
2024
Q4
$258K Buy
+3,320
New +$246K ﹤0.01% 866

Other funds holding DXCM

Waverly Advisors's DXCM Position: Q1 2026 in Review

Waverly Advisors increased its DexCom (DXCM) stake by 98% in Q1 2026, buying an estimated $1.89M and bringing the position to 54,733 shares worth $3.44M. The position accounts for 0.03% of the portfolio, ranked #508.

Waverly Advisors first reported a position in DXCM in Q4 2024 and has held it in 6 quarters since. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Waverly Advisors held 54,733 shares of DexCom worth $3.44M as of Q1 2026.
  • Waverly Advisors bought 27,150 DexCom shares in Q1 2026, an estimated $1.89M.
  • DexCom made up 0.03% of Waverly Advisors's portfolio in Q1 2026, its #508 holding.
  • Waverly Advisors first reported a position in DexCom in Q4 2024 and has held it in 6 quarters since.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Waverly Advisors's 13F filing for Q1 2026, filed 15 May 2026.